PDCD1 and triple-negative breast carcinoma: In the KEYNOTE-522 trial, the addition of pembrolizumab, a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1) and exhibits antitumor properties, to neoadjuvant chemotherapy, followed by adjuvant pembrolizumab administration, demonstrated significant improvements in pathological complete response rates and overall survival among patients with early-stage triple-negative breast cancer, while maintaining an acceptable safety profile [2-4].